Drugs / R0.6C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04862416 | May 2021 → Jun 2022 | Plasmodium falciparum malaria | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R0.6C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04862416 ↗ |
| Known as | R0.6C fusion protein | “The R0.6C fusion protein, consisting of Pfs48/45 domain 3 (6C) and the N-terminal region of P. falciparum glutamate-rich protein (R0), has previously been produced in...” PMID 38649867 ↗ Apr 2024 |
| Modality | Vaccine | “R0.6C vaccine” NCT04862416 ↗ |
| Route | Intramuscular | “R0.6C intramuscularly” NCT04862416 ↗ |